



FILE COPY

PATENT APPLICATION

RECEIPT #9 mw

Attorney Docket No.: A-67860-3/DJB/JJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MACK, et al.

Serial No.: 09/525,361

Filed: March 15, 2000

For: NOVEL METHODS OF
DIAGNOSING AND TREATING
BREAST CANCER,
COMPOSITIONS, AND METHODS
OF SCREENING FOR BREAST
CANCER MODULATORS

Examiner: Unknown

Group Art Unit: 1187

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Office of Initial Patent Examination's, Customer Service Center, Assistant Secretary and Commissioner of Patent and Trademarks, Washington, D.C. 20231 on 3-28-01.

Signature:

Mary McFarland
Mary McFarland

RECEIVED

AUG 07 2001

TECH CENTER 1600/2900

SECOND REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Office of Initial Patent Examinations
Customer Service Center
Assistant Secretary and
Commissioner of Patent and Trademarks
Washington, D.C. 20231

Sir:

Appended hereto is a copy of an Official Filing Receipt for the above-identified patent application with the corrections indicated in red ink.

In the "Continuing Data as Claimed by Applicant" portion of the receipt, after "AND A CIP OF 09/453,137 12/02/1999," please delete "WHICH IS" and insert -- AND A--.

The "Continuing Data as Claimed by Applicant" portion of the receipt will then correctly read as follows:

THIS APPLICATION IS A CIP OF 09/268,865 03/15/1999
AND A CIP OF 09/439,878 11/12/1999
AND A CIP OF 09/440,370 11/12/1999
AND A CIP OF 09/440,493 11/15/1999
AND A CIP OF 09/440,676 11/16/1999
AND A CIP OF 09/440,677 11/16/1999
AND A CIP OF 09/450,810 11/29/1999
AND A CIP OF 09/453,137 12/02/1999
AND A CIP OF 09/520,478 03/08/2000


RECEIVED
AUG 07 2001
TECH CENTER 1600/2900

Because this error was caused by the Patent Office, it is believed that no fee is necessary. However, if this belief is in error, the commissioner is authorized to charge any fee which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-67860-3/DJB/JJD).

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP

Date: March 28, 2001


James J. Diehl [Reg No. 47,527] for
Robin M. Silva [Reg No. 38,304]

Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
10472868(SF)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/525,361	03/15/2000	1635	1187	A-67860- 3/RMS/DAV	188	37	19

CONFIRMATION NO. 9370

CORRECTED FILING RECEIPT



OC000000005760034

Flehr Hohbach Test Albritton & Herbert LLP
Suite 3400 Four Embarcadero Center
San Francisco, CA 94111-4187

Date Mailed: 02/13/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David Mack, Menlo Park, CA;
Kurt C. Gish, San Francisco, CA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/268,865 03/15/1999
AND A CIP OF 09/439,878 11/12/1999
AND A CIP OF 09/440,370 11/12/1999
AND A CIP OF 09/440,493 11/15/1999
AND A CIP OF 09/440,676 11/16/1999
AND A CIP OF 09/440,677 11/16/1999
AND A CIP OF 09/450,810 11/29/1999
AND A CIP OF 09/453,137 12/02/1999
~~WHICH IS A CIP OF 09/520,478 03/08/2000~~

AND

Foreign Applications

If Required, Foreign Filing License Granted 05/12/2000

Projected Publication Date:

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators

Preliminary Class


514

Data entry by : SHEFFEY, CATHERINE

Team : OIPE

Date: 02/13/2001





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231